Jonathan E Lim
- SEC Documents
- Filings
- Personal financials
- Insider transactions
- Previous Companies
-
Ignyta, Inc.
Global Yacht Services (NASDAQ:HALO)
Sample Contracts with Jonathan E Lim
Ignyta, Inc. – Certain Material (Indicated by an Asterisk) Has Been Omitted From This Document Pursuant to a Request for Confidential Treatment. The Omitted Material Has Been Filed Separately With the Securities and Exchange Commission. Amended and Restated License, Development and Commercialization Agreement Dated as of March 22, 2017 by and Between Eli Lilly and Company and Ignyta, Inc. (May 1st, 2017)This Amended and Restated License, Development and Commercialization Agreement (this Agreement), dated as of March 22, 2017 (the Effective Date), is made by and between Eli Lilly and Company, an Indiana corporation (Lilly), and Ignyta, Inc., a Delaware corporation (Licensee). Lilly and Licensee are sometimes referred to herein individually as a Party and collectively as the Parties.
Ignyta, Inc. – Loan and Security Agreement (July 1st, 2016)THIS LOAN AND SECURITY AGREEMENT (this Agreement) dated as of June 30, 2016 (the Effective Date) by and among SILICON VALLEY BANK, a California corporation (Bank or SVB), as collateral agent (in such capacity, Collateral Agent), the Lenders listed on Schedule 1.1 hereof or otherwise a party hereto from time to time, including SVB in its capacity as a Lender and OXFORD FINANCE LLC, a Delaware limited liability company (Oxford) (each a Lender and collectively, the Lenders), and IGNYTA, INC., a Delaware corporation (Borrower), provides the terms on which the Lenders shall lend to Borrower and Borrower shall repay the Lenders. The parties agree as follows:
Loan and Security Agreement (March 1st, 2013)
This Separation Agreement and General Release of All Claims (Separation Agreement) is made by and between Halozyme Therapeutics, Inc. (Halozyme) and Jonathan E. Lim (Employee) as of December 2, 2010 with respect to the following facts:
The 2007 Senior Executive Incentive Plan of Halozyme Therapeutics, Inc. (the Company) set forth maximum cash and equity bonus awards for the Companys senior executive officers (the 2007 Incentive Plan). Maximum cash and equity bonus amounts were established for each executive officer (amounts for selected members of senior management are set forth in the table below) based upon the accomplishment of both individual and Company performance criteria during 2007. The maximum cash bonus amount for each executive officer represented 30% of that officers annual base salary, with the exception that the maximum cash bonus amount for the Companys Chief Executive Officer represented 40% of his base salary. The individual performance criteria for specific members of senior management varied from position to position, but all members of senior management had common Company performance goals. The Company performance criteria were based upon operational, clinical and financial performance objectives
This Rights Agreement (Rights Agreement), dated as of May 4, 2006, as amended on November 12, 2007, between Halozyme Therapeutics, Inc., a Nevada corporation (the Company), and Corporate Stock Transfer (the Rights Agent).
This AGREEMENT AND PLAN OF MERGER (this Agreement) dated as of November 14, 2007, by and between Halozyme Therapeutics, Inc., a Nevada corporation (HALO-Nevada), and Halozyme Therapeutics, Inc., a Delaware corporation and wholly-owned subsidiary of HALO-Nevada (HALO-Delaware), is made with respect to the following facts.
We, the President and Chief Executive Officer and the Secretary, respectively, of Halozyme Therapeutics, Inc., organized and existing under the General Corporation Law of the State of Delaware, in accordance with the provisions of Section 103 thereof, DO HEREBY CERTIFY:
SAN DIEGO, March 8, 2007 Halozyme Therapeutics, Inc. (AMEX: HTI), a biopharmaceutical company developing and commercializing recombinant human enzymes, today reported financial results for the three months and year ended December 31, 2006.
REGISTRATION RIGHTS AGREEMENT (this Agreement), dated as of December 5, 2006, by and between (i) Halozyme Therapeutics, Inc., a Nevada corporation (the Company), and (ii) Roche Finance Ltd, a Swiss company (the Investor).
We, the President and Chief Executive Officer and the Secretary, respectively, of Halozyme Therapeutics, Inc., organized and existing under Chapter 78 of the Nevada Revised Statutes, in accordance with the provisions of Section 78.1955 thereof, DO HEREBY CERTIFY:
This SECOND AMENDMENT TO THE EXCLUSIVE DISTRIBUTION AGREEMENT (this 2nd Amendment), effective as of December 2, 2005 (the 2nd Amendment Date), is entered into by and between BAXTER HEALTHCARE CORPORATION with its principal place of business at One Baxter Parkway, Deerfield, Illinois 60015-4633 (Baxter), and HALOZYME, INC. with its principal place of business at 11588 Sorrento Valley Road, Suite 17, San Diego, California 92121 (Halozyme).
This FIRST AMENDMENT TO THE LICENSE AGREEMENT (this First Amendment), effective as of December 30th, 2005 (the First Amendment Effective Date), is entered into by and between the University of Connecticut Health Center (UCHC), a public institution of higher education, c/o its Center for Science and Technology Commercialization, with a principal office at 263 Farmington Avenue, Farmington, CT 06030-6207, and Halozyme, Inc. (HALOZYME), a California Corporation, with a principal place of business at 11588 Sorrento Valley Road, Suite 17, San Diego, CA 92121, and is the first amendment to that LICENSE AGREEMENT (the License Agreement) between UCHC and Deliatroph Pharmaceuticals, Inc. (the predecessor-in-interest of HALOZYME) that was entered into as of November 15, 2002. Each of UCHC and HALOZYME are sometimes referred to herein as a party, collectively as the parties.
EXHIBIT 10.2 CONFIDENTIAL TREATMENT REQUESTED - REDACTED COPY CONFIDENTIAL TREATMENT REQUESTED: INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS OMITTED AND NOTED WITH "***." AN UNREDACTED VERSION OF THIS DOCUMENT HAS BEEN SUBMITTED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION. FIRST AMENDMENT TO THE EXCLUSIVE DISTRIBUTION AGREEMENT This FIRST AMENDMENT TO THE EXCLUSIVE DISTRIBUTION AGREEMENT (this "Amendment"), effective as of March 24, 2005, is entered into by and between BAXTER HEALTHCARE CORPORATION with its principal place of business at One Baxter Parkway, Deerfield, Illinois 60015-4633 ("Baxter"), and HALOZYME, INC. with its principal place of business at 11588 Sorrento Valley Road, Suite 17, San Diego, California 92121 ("Halozyme"), and is the first amendment to that EXCLUSIVE DIS
EXHIBIT 10.9 EXCLUSIVE DISTRIBUTION AGREEMENT THIS EXCLUSIVE DISTRIBUTION AGREEMENT (this "Agreement"), dated as of August 13, 2004 (the "Effective Date") is entered into between BAXTER HEALTHCARE CORPORATION with its principal place of business at One Baxter Parkway, Deerfield, Illinois 60015-4633 ("Baxter"), and HALOZYME, INC. with its principal place of business at 11588 Sorrento Valley Road, Suite 17, San Diego, California 92121 ("Halozyme"). WHEREAS the parties entered into the non-binding letter effective as of April 27, 2004 (the "Letter"), pursuant to which the parties contemplated negotiation of this Agreement, and for purposes of this Agreement, "Product" shall have the meaning set forth in Section 1 of the Letter; WHEREAS, Halozyme wishes to have Baxter promote, market, distribute and sell the Product and Baxter wishes to promote, market, distribute and sell the Product for Halozyme in the Territories as defined below; NOW
This AGREEMENT FOR SERVICES is made this __ day of November, 2003 (the Effective Date) by and between Avid Bioservices, Inc., a Delaware corporation, (hereinafter referred to as AVID), having its principal office at 14282 Franklin Avenue, Tustin, CA 92780, USA and Hyalozyme Therapeutics, Inc, a California corporation, (hereinafter referred to as "COMPANY"), having its principal office at 11588 Sorrento Valley Road, Suite-17, San Diego, CA 92121, USA.
THIS NON-EXCLUSIVE DISTRIBUTION AGREEMENT (this Agreement), dated as of January 30, 2004 (the Effective Date) is entered into between MID ATLANTIC DIAGNOSTICS, INC. (Distributor), a New Jersey corporation, having a place of business located at 438 North Elmwood Road, Marlton, NJ 08053, and HALOZYME THERAPEUTICS, INC. (Halozyme), a California corporation, having a principal place of business at 11588 Sorrento Valley Road, Suite 17, San Diego, CA 92121. The parties hereby agree as follows:
THIS NON-EXCLUSIVE DISTRIBUTION AGREEMENT (this Agreement), dated as of February 9, 2004 (the Effective Date) is entered into between MediCult A/S (Distributor), CVR-no. 10975077, a Danish corporation, having a place of business located at Mollehaven 12, DK-4040 Jyllinge, Denmark, and HALOZYME THERAPEUTICS, INC. (Halozyme), a California corporation, having a principal place of business at 11588 Sorrento Valley Road, Suite 17, San Diego, CA 92121. The parties hereby agree as follows:
THIS NON-EXCLUSIVE DISTRIBUTION AGREEMENT (this Agreement), dated as of April 13, 2004 (the Effective Date) is entered into between COOK OB/GYN INCORPORATED (Distributor), an Indiana corporation, having a place of business located at 1100 West Morgan Street, Spencer, Indiana 47460, and HALOZYME THERAPEUTICS, INC. (Halozyme), a California corporation, having a principal place of business at 11588 Sorrento Valley Road, Suite 17, San Diego, CA 92121. The parties hereby agree as follows: